C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) announced an inducement grant of non-qualified stock options covering 162,880 shares to one new employee, approved by independent directors on February 9, 2026.

The options have an exercise price equal to the closing share price on the grant date and vest over four years (25% after one year, then monthly over three years), subject to continued employment.

News Market Reaction

-2.20%

3 alerts

-2.20% News Effect

-$4M Valuation Impact

$184M Market Cap

0.2x Rel. Volume

On the day this news was published, CCCC declined 2.20%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $184M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current price: $1.82 Price change 24h: 6.43% Inducement option grant: 162,880 shares +5 more

8 metrics

Current price $1.82 As of pre-news market context

Price change 24h 6.43% Move prior to or into the news

Inducement option grant 162,880 shares Non-qualified stock options to one new employee

Grant date February 9, 2026 Inducement Grant made on Grant Date

Initial vesting 25% of shares Vest on first-year anniversary of start date

Remaining vesting 36 monthly installments Remainder vesting over four-year period

Shelf registration size $400,000,000 Total capacity under S-3 shelf filed Nov 21, 2025

ATM component $125,000,000 Common stock sales agreement prospectus within shelf

Market Reality Check

Price: $1.84 Vol: Volume 821,762 vs 20-day ...

low vol

$1.84 Last Close

Volume Volume 821,762 vs 20-day average 1,516,228 ahead of this routine option grant news. low

Technical Shares at $1.82, trading below 200-day MA of $2.14 and 51.08% under the 52-week high.

Peers on Argus

CCCC gained 6.43% while peers were mixed: ELTX +7.35%, NTHI +2.52%, TRDA +2.91%,...

CCCC gained 6.43% while peers were mixed: ELTX +7.35%, NTHI +2.52%, TRDA +2.91%, SLS +3.9%, IPHA -2.29%. No coordinated sector momentum flagged.

Historical Context

5 past events · Latest: Feb 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	Conference participation	Neutral	-6.0%	Announcement of participation in Guggenheim Emerging Outlook Biotech Summit.
Jan 26	Inducement option grant	Neutral	+3.4%	Inducement stock option grant to a new employee under Nasdaq rules.
Jan 14	Strategic pipeline update	Positive	+0.9%	Outlined milestones to advance cemsidomide and discovery programs through 2028.
Nov 25	Conference participation	Neutral	+0.8%	Evercore healthcare conference fireside chat announcement and webcast details.
Nov 06	Earnings and update	Positive	+0.4%	Q3 2025 financial results plus financing and cemsidomide clinical updates.

Pattern Detected

Recent stock reactions to non-clinical news (conferences, inducement grants) have been modest and mixed, while larger strategic and financial updates have seen small positive moves.

Recent Company History

Over the past few months, C4 Therapeutics has reported conference participation, inducement grants, strategic program milestones, and Q3 2025 financials. Strategic updates on cemsidomide and financing on Nov 6, 2025 and Jan 14, 2026 saw small positive moves. Conference notices on Nov 25, 2025 and Feb 4, 2026 produced muted or negative reactions, while a prior inducement grant on Jan 26, 2026 coincided with a modest gain. Today’s similar HR-related grant fits this pattern of limited but sometimes positive impact.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-21

$400,000,000 registered capacity

An effective S-3 shelf dated Nov 21, 2025 allows C4 Therapeutics to offer up to $400,000,000 in various securities, including up to $125,000,000 of common stock via an at-the-market program. The filing is intended to provide flexible access to capital for general corporate purposes; usage_count is 0 in the provided context.

Market Pulse Summary

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant of 162,880 non-qualifie...

Analysis

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant of 162,880 non-qualified stock options to a new employee, with vesting over four years. It follows earlier strategic and financing updates on Jan 14 and Nov 6, 2025, which outlined funding to end of 2028 and cemsidomide milestones. Investors may focus more on upcoming clinical and financial events than on this routine compensation-related item.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, exercise price, vesting

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"The Inducement Grant was granted as a material inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"approved the grant of non-qualified stock options to purchase 162,880 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"The Inducement Grant has an exercise price per share that is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on February 9, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors: 
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com 

Media: 
Loraine Spreen 
Senior Director, Corporate Communications & Patient Advocacy 
LSpreen@c4therapeutics.com 

FAQ

What did C4 Therapeutics (CCCC) announce on February 9, 2026 about an inducement grant?

C4 Therapeutics granted non-qualified stock options for 162,880 shares to one new employee as an inducement. According to the company, the grant was approved by independent directors under Nasdaq Listing Rule 5635(c)(4) and dated February 9, 2026.

What is the exercise price for the CCCC inducement grant issued February 9, 2026?

The exercise price equals C4 Therapeutics' closing common stock price on the grant date. According to the company, the options were set at the closing price on February 9, 2026, matching Nasdaq inducement requirements.

How does the vesting schedule work for C4 Therapeutics' 162,880-share option grant (CCCC)?

The options vest over four years with 25% after the first-year anniversary and monthly thereafter. According to the company, the remaining shares vest in thirty-six equal monthly installments, subject to continued employment through each vesting date.

Why did C4 Therapeutics (CCCC) provide an inducement grant under Nasdaq Listing Rule 5635(c)(4)?

The grant was provided as a material inducement for a new employee to join the company. According to the company, the inducement was made in accordance with Nasdaq Listing Rule 5635(c)(4) and approved by independent directors.

Will the C4 Therapeutics inducement grant for 162,880 shares dilute existing shareholders immediately?

The grant creates potential dilution only upon option exercise, not immediate dilution of outstanding shares. According to the company, dilution depends on future exercise and any withholding or share-settlement mechanics tied to the options.